Dupixent was previously granted Orphan Drug Designation by ... in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Dupixent was previously granted Orphan Drug ... filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024. Any forward-looking ...

Dupixent was previously granted Orphan Drug Designation by ... and painful lesions. The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Dupixent was previously granted Orphan Drug Designation by ... found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, ...

If approved, Dupixent would be the first and only targeted ... The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being more prone ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...